Pascal Soriot’s stunning corporate turnaround story at AstraZeneca is now mired in vaccine politics and doubt.
Category: Daily Cover
Europe’s Mixed Messages On AstraZeneca Vaccine Jeopardize Global Covid Response
The continent’s suspensions are eroding vaccine confidence just when the world needs it the most.
Politics, Not Science, May Be Behind Suspensions Of AstraZeneca’s Covid Vaccine
Multiple experts say that the drug company’s vaccine is being unfairly targeted by EU countries, hindering plans to roll it out worldwide at a critical time.
Little-Known Publicly Traded Company Given Massive Deal To Manufacture One-Shot Covid-19 Vaccine
While Johnson & Johnson developed and got FDA authorization for its one-dose vaccine, it won’t be the one manufacturing it – that big task and huge windfall goes to a mostly unknown company in Maryland.
Billionaire Clover Health CEO Vivek Garipalli’s Expletive-Ridden Tirade
With his health insurance company facing an army of short sellers and investigations from the SEC and DOJ, the pugnacious chief executive responded with an epic late-night meltdown.
This College Professor Became An Overnight Billionaire Fighting Covid
Carl Hansen’s Abcellera Biologics scored big helping Eli Lilly develop antibodies to treat symptoms of Covid-19.
Why A Tech Billionaire’s $50 Million Bet On A Covid Testing Firm Is Still Waiting For FDA Approval
Diagnostic firm Fluxergy’s pivot to Covid-testing was supposed to give it a huge boost – but even with backing from Kingston Technology’s John Tu, it’s stuck in limbo.
FDA Authorizes Pfizer And BioNTech’s Covid-19 Vaccine For Use In The United States
On Friday, the U. S. Food and Drug Administration granted Emergency Use Authorization to Pfizer and BioNTech’s Covid-19 vaccine, the first vaccine that will be available for public use in the U. S.
Survivors & Thrivers
Amid a pandemic implosion, these startups showcase the strength, diversity and adaptability of America’s entrepreneurs—and provide hope for the country’s economic future.
The Scientologist Billionaire Trying To Make A New Antibiotic
Bob Duggan could easily have called it a career in 2015, after he sold Pharma- cyclics, his cancer-drug biotech, to AbbVie.
